HK1164159A1 - A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib - Google Patents

A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib

Info

Publication number
HK1164159A1
HK1164159A1 HK12105129.9A HK12105129A HK1164159A1 HK 1164159 A1 HK1164159 A1 HK 1164159A1 HK 12105129 A HK12105129 A HK 12105129A HK 1164159 A1 HK1164159 A1 HK 1164159A1
Authority
HK
Hong Kong
Prior art keywords
sunitinib
sorafenib
erlotinib
quinolin
pyrrolo
Prior art date
Application number
HK12105129.9A
Other languages
English (en)
Inventor
Thomas C K Chan
Dennis S France
Kenichi Ishii
Paolo Pucci
Original Assignee
Arqule Inc
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc, Kyowa Hakko Kirin Co Ltd filed Critical Arqule Inc
Publication of HK1164159A1 publication Critical patent/HK1164159A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12105129.9A 2009-02-12 2012-05-24 A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib HK1164159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15213809P 2009-02-12 2009-02-12
US17047109P 2009-04-17 2009-04-17
PCT/US2010/023893 WO2010093789A2 (en) 2009-02-12 2010-02-11 Combinational compositions and methods for treatment of cancer

Publications (1)

Publication Number Publication Date
HK1164159A1 true HK1164159A1 (en) 2012-09-21

Family

ID=42126095

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105129.9A HK1164159A1 (en) 2009-02-12 2012-05-24 A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib

Country Status (14)

Country Link
US (2) US20100297075A1 (xx)
EP (1) EP2396003B1 (xx)
JP (1) JP5687209B2 (xx)
KR (1) KR101620654B1 (xx)
CN (1) CN102481299B (xx)
AU (1) AU2010213696B2 (xx)
BR (1) BRPI1007972A2 (xx)
CA (1) CA2752232C (xx)
HK (1) HK1164159A1 (xx)
IL (1) IL214348A (xx)
MX (1) MX2011008584A (xx)
TW (1) TWI460178B (xx)
WO (1) WO2010093789A2 (xx)
ZA (1) ZA201105611B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396003B1 (en) 2009-02-12 2013-04-17 ArQule, Inc. A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
WO2012003421A2 (en) 2010-07-01 2012-01-05 Arqule, Inc. Combinational compositions and methods for treatment of cancer
WO2012030896A2 (en) 2010-09-01 2012-03-08 Arqule, Inc. Methods for treatment of non-small cell lung cancer
JP6013359B2 (ja) * 2010-12-17 2016-10-25 ノバルティス アーゲー 組合せ
WO2012088491A2 (en) * 2010-12-23 2012-06-28 Arqule, Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
AU2012223528A1 (en) * 2011-03-02 2013-10-24 Joseph M. Fayad Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
AU2012278831A1 (en) * 2011-07-07 2014-01-16 Arqule, Inc Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
US9000005B2 (en) 2012-04-23 2015-04-07 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
CN102757435B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
PT3388420T (pt) * 2015-12-07 2022-09-20 Hinova Pharmaceuticals Inc Compostos de quinolina, método de preparação dos mesmos e uso dos mesmo como fármaco inibidor do transportador de urato
CA3053739C (en) 2017-02-15 2023-02-14 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
CN108546244B (zh) * 2018-07-05 2021-04-23 南昌航空大学 一种3,3’-二吲哚乙烷类化合物的合成方法
US20240058335A1 (en) * 2021-01-08 2024-02-22 Duke University Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway
WO2024105699A1 (en) * 2022-11-18 2024-05-23 Council Of Scientific And Industrial Research Composition for treating paclitaxel-resistant breast cancer and method for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN101941970B (zh) * 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
EP2170870B1 (en) * 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
EP2396003B1 (en) 2009-02-12 2013-04-17 ArQule, Inc. A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
WO2012003421A2 (en) * 2010-07-01 2012-01-05 Arqule, Inc. Combinational compositions and methods for treatment of cancer
WO2012030896A2 (en) * 2010-09-01 2012-03-08 Arqule, Inc. Methods for treatment of non-small cell lung cancer

Also Published As

Publication number Publication date
CN102481299A (zh) 2012-05-30
EP2396003B1 (en) 2013-04-17
IL214348A (en) 2015-05-31
IL214348A0 (en) 2011-09-27
JP2012517477A (ja) 2012-08-02
CN102481299B (zh) 2015-02-25
TWI460178B (zh) 2014-11-11
JP5687209B2 (ja) 2015-03-18
MX2011008584A (es) 2012-01-27
US20150328208A1 (en) 2015-11-19
AU2010213696B2 (en) 2015-10-01
AU2010213696A1 (en) 2011-08-18
US20100297075A1 (en) 2010-11-25
CA2752232C (en) 2016-11-22
ZA201105611B (en) 2012-10-31
KR20110118817A (ko) 2011-11-01
CA2752232A1 (en) 2010-08-19
EP2396003A2 (en) 2011-12-21
WO2010093789A2 (en) 2010-08-19
KR101620654B1 (ko) 2016-05-12
TW201043626A (en) 2010-12-16
WO2010093789A3 (en) 2010-12-02
WO2010093789A8 (en) 2011-03-17
BRPI1007972A2 (pt) 2016-09-13
US9642847B2 (en) 2017-05-09

Similar Documents

Publication Publication Date Title
HK1164159A1 (en) A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
IL212339A (en) Pyrolobenzodiazepine derivatives and processes for their preparation
ZA200806392B (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists
EP2376659A4 (en) METHODS, COMPOSITIONS AND NEEDS FOR DETECTION OF ALLELIC VARIANTS
PL2373951T3 (pl) Pomiar średnicy na tokarkach
TWI347842B (en) Tricyclic compounds, compositions, and methods
IL212417A0 (en) Lipidated imidazoquinoline derivatives
GB0702259D0 (en) 7-azaindole derivatives
AP2010005202A0 (en) Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
GB0625842D0 (en) Indolizine derivatives
IL205189A (en) 7,6-dihydro-h5-imidazo [2,1- α] imidazole-3-carboxamide and their pharmaceutical preparations
PL2283194T3 (pl) Zespół pojemnika możliwego do ryglowania
HK1155160A1 (en) Compositions with and process for methylmorpholin-substituted pyrido
IL195190A (en) 83cd soluble for use in combination therapy with immune suppressant
GB0814740D0 (en) Chain transmission for use in engine
IL207223A0 (en) Pyrrolidinyl derivatives and uses thereof
EP2310393A4 (en) ARTEMISININE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS
PL2276347T3 (pl) Toltrazuril o ulepszonych właściwościach rozpuszczania
GB0818748D0 (en) Improvements in packaging
GB0702265D0 (en) 7-Azaindole derivatives
IL208021A0 (en) 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents
WO2009113091A3 (en) Pharmaceutical compositions comprising valsartan
EP2238035B8 (en) Rotary-platform and foldable-column wrapping machine
EP2334990A4 (en) Device for reducing the preparation time in ovens having rotary basket

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180211